| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.38 M USD | -31.54 M USD | -37.61 M USD | -45.08 M USD | -41.39 M USD | -30.63 M USD | -20.77 M USD | -18.39 M USD |
| Depreciation & Amortization | 1.10 M USD | 1.10 M USD | 1.40 M USD | 1.40 M USD | 700000 USD | 300000 USD | 200000 USD | 100000 USD |
| Stock-Based Compensation | 21.23 M USD | 22.95 M USD | 22.10 M USD | 16.45 M USD | 10.53 M USD | 3.20 M USD | 364000 USD | 366000 USD |
| Capital Expenditures | 452000 USD | 1.45 M USD | 807000 USD | 1.32 M USD | 3.67 M USD | 911000 USD | 720000 USD | 316000 USD |
| Cash Flow from Investing | 30.48 M USD | 17.48 M USD | -2.01 M USD | -4.22 M USD | -46.26 M USD | 12.69 M USD | -14.23 M USD | 200000 USD |
| Cash Flow from Financing | 833000 USD | 1.36 M USD | 21.40 M USD | 2.42 M USD | 4.46 M USD | 234.83 M USD | 45.62 M USD | 12.11 M USD |
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Buybacks | — | — | 0 USD | 27000 USD | 26000 USD | 21000 USD | 12000 USD | 0 USD |
| Free Cash Flow | -32.83 M USD | -32.98 M USD | -38.42 M USD | -46.40 M USD | -45.06 M USD | -31.54 M USD | -21.48 M USD | -18.71 M USD |
Pulmonx Corporation is a leading medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company focuses on developing and commercializing advanced technologies that offer new options for patients suffering from lung disorders. One of its flagship products, the Zephyr Valve, is a tiny device designed for bronchoscopic lung volume reduction in severe emphysema patients, providing an alternative to invasive surgical procedures. Pulmonx's innovative solutions impact the healthcare sector by improving patient outcomes and offering healthcare providers effective, less invasive treatment options. By driving advancements in respiratory care, Pulmonx plays a significant role in the growing medical device industry, particularly within the respiratory segment, as the demand for novel therapeutic options for chronic lung diseases increases. Headquartered in Redwood City, California, the company collaborates with medical professionals worldwide to expand access to its life-changing technologies.